[Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.].
C, P., L, D., N, A., L, D., G, R., I, D., A, A., I, E., N, M., & AP, M. (2026). [Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.].. Recenti progressi in medicina. https://doi.org/10.1701/4743.47601
C P, L D, N A, L D, G R, I D, et al. [Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.].. Recenti progressi in medicina. 2026; doi: 10.1701/4743.47601
C P, L D, N A, et al. [Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.].[J]. Recenti progressi in medicina. 2026. DOI: 10.1701/4743.47601.
@article{c2026,
author = {Piccinni C and Dondi L and Ambrosio N and Dondi L and Ronconi G and Dell'Anno I and Addesi A and Esposito I and Martini N and Maggioni AP},
title = {[Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.].},
journal = {Recenti progressi in medicina},
year = {2026},
doi = {10.1701/4743.47601},
note = {PMID: 42459101},
}
TY - JOUR AU - Piccinni C AU - Dondi L AU - Ambrosio N AU - Dondi L AU - Ronconi G AU - Dell'Anno I AU - Addesi A AU - Esposito I AU - Martini N AU - Maggioni AP TI - [Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.]. T2 - Recenti progressi in medicina PY - 2026 DO - 10.1701/4743.47601 AN - PMID:42459101 ER -
RATIONALE: This study analyses, within Italian clinical practice, the epidemiology, healthcare resource utilization, and direct costs for the National Health Service (NHS) of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). METHODS: From the ReS healthcare administrative database (4.6 million beneficiaries in 2022), patients with ATTR-CM were identified (2014-2022) through dispensation of tafamidis 61 mg or diagnosis of heart failure/arrhythmic cardiomyopathy with a compatible diagnostic work-up. Prevalence, clinical characteristics, mortality, treatments, healthcare resource utilization, and costs were estimated during the 1-year follow-up. RESULTS: 867 patients with ATTR-CM were identified in 2022 (male: 63%; mean age: 73 years; ≥3 comorbidities: 88.6%). During follow-up, 13% of patients died; 46% were hospitalized under ordinary care; 46.8% visited the emergency department; 96.5% received outpatient specialist care. Tafamidis 61 mg was dispensed to 49 patients (5.7%). The average annual cost per patient, borne by the NHS, was €17,284 (59.7% attributable to pharmaceuticals). CONCLUSIONS: The impact of ATTR-CM on the NHS is considerable, due to advanced patient age, multimorbidity, polypharmacy, and frequent hospitalizations, both related and unrelated to ATTR-CM.